Zydus gets final USFDA nod to sell Voriconazole Tab
Estimates sale of US$ 92.8-mn for the tablet, used to treat fungal infections25-05-2016
Zydus gets final USFDA nod to sell Voriconazole Tab
Estimates sale of US$ 92.8-mn for the tablet, used to treat fungal infectionsFixes Book Closure for AGM
Zydus Wellness Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from July 25, 2016 to August 03, 2016 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Company to be held on August 03, 2016.Zydus Wellness Q4 net profit at Rs 26 crore
Zydus Wellness had posted a net profit of Rs 20.18 crore in the same period a year ago, Zydus Wellness said in a BSE filing.Form A for March 31, 2016
Zydus Wellness Ltd has informed BSE about : 1. Standalone Form A for the period ended March 31, 20162. Consolidated Form A for the period ended March 31, 2016Standalone & Consolidated Financial Results, Auditors Report, Results Press Release for March 31, 2016
Zydus Wellness Ltd has informed BSE about : 1. Standalone Financial Results for the period ended March 31, 20162. Consolidated Financial Results for the period ended March 31, 20163. Standalone Auditors Report for the period ended March 31, 20164. Consolidated Auditors Report for the period ended March 31, 20165. Result Press Release for the period ended March 31, 2016Schedule of Analyst / Institutional Investors' Meet
Zydus Wellness Ltd has informed BSE regarding "Schedule of Analyst / Institutional Investors' Meet".Board Intimation for Results & Closure of Trading Window
Zydus Wellness Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on May 12, 2016 to consider apart from other agenda items to approve the audited financial results for the quarter / year ended on March 31, 2016.Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI [Prohibition of Insider Trading] Regulations, 2015, the Trading Window will remain closed...Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended March 31, 2016
Zydus Wellness Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended March 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.Shareholding for the Period Ended March 31, 2016
Zydus Wellness Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2016. For more details, kindly Click here